Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Gallo G, Strober B, Van Voorhees A. Lockshin B, et al. Among authors: zhu b. Dermatol Ther. 2021 Mar;34(2):e14808. doi: 10.1111/dth.14808. Epub 2021 Feb 15. Dermatol Ther. 2021. PMID: 33491259 Free PMC article.
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. Edson-Heredia E, et al. Among authors: zhu b. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13. J Eur Acad Dermatol Venereol. 2016. PMID: 25773781 Clinical Trial. No abstract available.
Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA, Zhu B, Guo J, Nikai E, Ojeh C, Malatestinic W, Goldblum O, Kornberg LJ, Wu JJ. Foster SA, et al. Among authors: zhu b. J Manag Care Spec Pharm. 2016 Apr;22(4):396-405. doi: 10.18553/jmcp.2016.22.4.396. J Manag Care Spec Pharm. 2016. PMID: 27023693 Free PMC article.
OBJECTIVES: To (a) evaluate demographic and clinical characteristics of psoriasis patients who have treatment patterns suggestive of failure to a newly initiated biologic agent (treatment-regimen failures) compared with those who do not (non-treatment-regimen failures) and (b …
OBJECTIVES: To (a) evaluate demographic and clinical characteristics of psoriasis patients who have treatment patterns suggestive of failure …
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: zhu b. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. Guenther L, et al. Among authors: zhu b. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28573743 Clinical Trial.
10,514 results
You have reached the last available page of results. Please see the User Guide for more information.